Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model

被引:436
作者
Abrey, Lauren E.
Ben-Porat, Leah
Panageas, Katherine S.
Yahalom, Joachim
Berkey, Brian
Curran, Walter
Schultz, Christopher
Leibel, Steven
Nelson, Diana
Mehta, Minesh
DeAngelis, Lisa M.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[4] Radiat Therapy Oncol Grp, Philadelphia, PA USA
[5] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[6] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
[7] Stanford Comprehens Canc Ctr, Stanford, CA USA
[8] Mayo Clin, Div Radiat Oncol, Rochester, MN USA
关键词
D O I
10.1200/JCO.2006.08.2941
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The purpose of this study was to analyze prognostic factors for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that could be applied to the care of patients and the design of prospective clinical trials. Patients and Methods Three hundred thirty-eight consecutive patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) between 1983 and 2003 were analyzed. Standard univariate and multivariate analyses were performed. In addition, a formal cut point analysis was used to determine the most statistically significant cut point for age. Recursive partitioning analysis (RPA) was used to create independent prognostic classes. An external validation set obtained from three prospective Radiation Therapy Oncology Group (RTOG) PCNSL clinical trials was used to test the RPA classification. Results Age and performance status were the only variables identified on standard multivariate analysis. Cut point analysis of age determined that patients age <= 50 years had significantly improved outcome compared with older patients. RPA of 282 patients identified three distinct prognostic classes: class 1 (patients <50 years), class 2 (patients >= 50; Karnofsky performance score [KPS] >= 70) and class 3 (patients >= 50; KPS <70). These three classes significantly distinguished outcome with regard to both overall and failure-free survival. Analysis of the RTOG data set confirmed the validity of this classification. Conclusion The MSKCC prognostic score is a simple, statistically powerful model with universal applicability to patients with newly diagnosed PCNSL. We recommend that it be adopted for the management of newly diagnosed patients and incorporated into the design of prospective clinical trials.
引用
收藏
页码:5711 / 5715
页数:5
相关论文
共 18 条
[1]   Treatment for primary CNS lymphoma: The next step [J].
Abrey, LE ;
Yahalom, J ;
DeAngelis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3144-3150
[2]   Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Long-term survival and prognostic factors [J].
Bessell, EM ;
Graus, F ;
Lopez-Guillermo, A ;
Lewis, SA ;
Villa, S ;
Verger, E ;
Petit, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02) :501-508
[3]   Importance of radiotherapy in the outcome of patients with primary CNS lymphoma:: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments [J].
Bessell, EM ;
López-Guillermo, A ;
Villá, S ;
Verger, E ;
Nomdedeu, B ;
Petit, J ;
Byrne, P ;
Montserrat, E ;
Graus, F .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :231-236
[4]  
Breiman L., 1998, CLASSIFICATION REGRE
[5]   Primary central nervous system lymphoma: Age and performance status are more important than treatment modality [J].
Corry, J ;
Smith, JG ;
Wirth, A ;
Quong, G ;
Liew, KH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (03) :615-620
[6]   PRIMARY CNS LYMPHOMA - COMBINED TREATMENT WITH CHEMOTHERAPY AND RADIOTHERAPY [J].
DEANGELIS, LM ;
YAHALOM, J ;
HEINEMANN, MH ;
CIRRINCIONE, C ;
THALER, HT ;
KROL, G .
NEUROLOGY, 1990, 40 (01) :80-86
[7]   Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10 [J].
DeAngelis, LM ;
Seiferheld, W ;
Schold, SC ;
Fisher, B ;
Schultz, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4643-4648
[8]   Prognostic scoring system for primary CNS lymphomas: The international extranodal lymphoma study group experience [J].
Ferreri, AJM ;
Blay, JY ;
Reni, M ;
Pasini, F ;
Spina, M ;
Ambrosetti, A ;
Calderoni, A ;
Rossi, A ;
Vavassori, V ;
Conconi, A ;
Devizzi, L ;
Berger, F ;
Ponzoni, M ;
Borisch, B ;
Tinguely, M ;
Cerati, M ;
Milani, M ;
Orvieto, E ;
Sanchez, J ;
Chevreau, C ;
Dell'Oro, S ;
Zucca, E ;
Cavalli, F .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :266-272
[9]   Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases [J].
Gaspar, LE ;
Scott, C ;
Murray, K ;
Curran, W .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04) :1001-1006
[10]  
Mazumdar M, 2000, STAT MED, V19, P113, DOI 10.1002/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO